Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | PDE6D | O43924 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538 | 0.89 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL8846682 | 0.88 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10305922 | 0.87 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL696979 | 0.87 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL696978 | 0.87 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL22604013 | 0.86 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12074037 | 0.86 | HMGCR (0.68) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL22894711 | 0.86 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL8193721 | 0.86 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4620964 | 0.85 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017137469-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2017-08-17 | — | — | WO | disclosed |
| EP-2788341-B1 | PROCESS FOR THE PREPARATION OF A THIOPRECURSOR FOR STATINS | DSM SINOCHEM PHARM NL BV (NL) | 2017-04-05 | — | — | EP | disclosed |
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| EP-2350025-A1 | AN IMPROVED PROCESS FOR PREPARING PYRIMIDINE PROPENALDEHYDE | Aurobindo Pharma Limited (IN) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | MALLELA SAMBHU PRASAD SARMA | 2011-07-21 | — | — | US | disclosed |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | MALLELA SAMBHU PRASAD SARMA | 2011-07-21 | — | — | US | disclosed |
| US-7851624-B2 | Triol form of rosuvastatin and synthesis of rosuvastatin | TEVA PHARAMACEUTICAL INDUSTRIES LTD. (IL) | 2010-12-14 | — | — | US | disclosed |
| US-7777056-B2 | Method for manufacture of 4-hydroxy pyran-2-one derivatives | LUPIN LTD. (IN) | 2010-08-17 | — | — | US | disclosed |
| EP-1697338-A2 | PROCESS FOR PREPARATION OF STATINS WITH HIGH SYN TO ANTI RATIO | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-09-06 | — | — | EP | disclosed |
| US-20050197501-A1 | Processes for preparing calcium salt forms of statins | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1425287-A4 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMA (IL) | 2005-09-07 | — | — | EP | disclosed |
| US-20050159615-A1 | Process for preparation of statins with high syn to anti ratio | ENTIRE INTEREST. | 2005-07-21 | — | — | US | disclosed |
| WO-2005063728-A2 | PROCESS FOR PREPARATION OF STATINS WITH HIGH SYN TO ANTI RATIO | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-07-14 | — | — | WO | disclosed |
| US-20040176615-A1 | Processes for preparing calcium salt forms of statins | NIDDAM-HILDESHEIM VALERIE (IL) | 2004-09-09 | — | — | US | disclosed |
| US-6777552-B2 | FROM AN ESTER DERIVATIVE OR PROTECTED ESTER DERIVATIVE OF THE STATIN BY USING CALCIUM HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-08-17 | — | — | US | disclosed |
| EP-1425287-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-09 | — | — | EP | disclosed |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-06-19 | — | — | US | disclosed |
| WO-2003016317-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159615-A1 | Process for preparation of statins with high syn to anti ratio | HMGCR, SYNJ1, SYNJ2 | HMGCR 1/4885ALDH1A1 4683/4885CYP3A4 1293/4885 |
| US-20050197501-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | HMGCR 1/4885ALDH1A1 4578/4885CYP3A4 124/4885 |
| US-20040176615-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | HMGCR 1/4885ALDH1A1 4578/4885CYP3A4 124/4885 |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | DPYD, NOX4, RPIA | HMGCR 5/4885ALDH1A1 36/4885CYP3A4 63/4885 |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | HMGCR 1/4885ALDH1A1 4578/4885CYP3A4 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.